Amplify Bluestar Israel Technology ETF (ITEQ)
- Previous Close
43.75 - Open
43.78 - Bid 32.45 x 1000
- Ask 54.01 x 1000
- Day's Range
43.01 - 43.78 - 52 Week Range
35.75 - 49.33 - Volume
2,791 - Avg. Volume
7,090 - Net Assets 87.07M
- NAV 43.32
- PE Ratio (TTM) 20.45
- Yield 0.00%
- YTD Daily Total Return -6.35%
- Beta (5Y Monthly) 1.07
- Expense Ratio (net) 0.75%
The index tracks the performance of exchange-listed Israeli technology operating companies. The fund will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Amplify ETFs
Fund Family
Technology
Fund Category
87.07M
Net Assets
2015-11-02
Inception Date
Performance Overview: ITEQ
Trailing returns as of 4/19/2024. Category is Technology.
People Also Watch
Holdings: ITEQ
Top 10 Holdings (58.45% of Total Assets)
Sector Weightings
Recent News: ITEQ
Research Reports: ITEQ
Daily – Vickers Top Buyers & Sellers for 04/19/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingBullishPrice TargetAnalyst Report: Airbnb, Inc.
Started in 2008, Airbnb is the world’s largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb’s platform offered over 7 million active accommodation listings as of Sept. 30, 2023. Listings from the company’s over 4 million hosts are spread over almost every country in the world. In the fourth quarter of 2022, 47% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
RatingNeutralPrice TargetAnalyst Report: Taiwan Semiconductor Manufacturing Company Limited
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with almost 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
RatingBullishPrice Target